Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Northeast Pharma to Build $750 Million Antibiotic Facility

publication date: Dec 20, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Northeast Pharmaceutical Group will invest five billion RMB ($750 million) to build a production facility for phosphonomycin, a broad-spectrum antibiotic. Northeast Pharma holds a 90% market share for phosphonomycin in China. It currently sells 400 million units of the drug each year, but will have capacity of 1 billion units with the new facility. More details....

Stock Symbol: (SHEX: 000597)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...